Moldàvia - romanès - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

balkan pharmaceuticals srl, sc - glibenclamidum - comprimate - 5 mg

Moldàvia - romanès - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

lilly france s.a.s. - insulinum lispro - solutie injectabila in cartus - 100 ui/ml

Unió Europea - romanès - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - agenți antineoplazici - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.

Unió Europea - romanès - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - mielom multiplu - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Unió Europea - romanès - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - alți agenți antineoplazici - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Unió Europea - romanès - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - mielom multiplu - agenți antineoplazici - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Unió Europea - romanès - EMA (European Medicines Agency)

janssen-cilag international n.v. - talquetamab - mielom multiplu - agenți antineoplazici - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Moldàvia - romanès - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

farmaprim srl - fluocinoloni acetonidum - unguent - 0,25 mg/g

Moldàvia - romanès - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

lekpharm srl - fenspiridi hydrochloridum - comprimate filmate - 80 mg

Moldàvia - romanès - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

fsp materia medica holding srl - o combinatie - comprimate de supt